# Methylene Blue

> Methylene blue is a synthetic phenothiazine compound with a long history of clinical use, most notably for treating methemoglobinemia and as an antimalarial and diagnostic dye. In recent years, low oral doses have drawn interest for potential cognitive and mitochondrial-support applications, distinct from its higher-dose clinical uses. Its long medical track record means more toxicological data exist for it than for many newer compounds, but the off-label, low-dose cognitive-enhancement use case has not been rigorously studied. It carries clinically significant interaction risks, particularly with serotonergic medications, which set it apart from most substances on this site. It is a distinct chemical class from injectable peptides, included here for its metabolic and mitochondrial research relevance.

- URL: https://www.lifeconverted.com/peptides/methylene-blue
- Also known as: Methylthioninium Chloride
- Primary category: Metabolic
- Effectiveness rank: #8 in Cognitive & Neuro; #7 in Metabolic
- Evidence level: Moderate evidence
- Route: Oral (Historically given intravenously in clinical settings, such as for methemoglobinemia; low-dose oral formulations are used for off-label cognitive and metabolic purposes.)
- Dose range: 5-30 mg
- Dose tiers: low 5 mg; moderate 15 mg; high 30 mg
- Half-life: Approximately 5-6.5 hours in humans.
- Timing: Morning
- Cycle: 4-6 weeks on, 2 weeks off (Conservative cycling is often suggested given limited long-term safety data at low, off-label doses.)
- Storage: Store in a dark, airtight container at room temperature; protect from light to prevent degradation.

## Mechanism of action

Methylene blue acts as an alternative electron carrier in the mitochondrial electron transport chain, accepting electrons from NADH and donating them further along the chain, which may support ATP production under conditions of mitochondrial stress. At low concentrations it also shows antioxidant behavior by cycling between oxidized and reduced states. It additionally inhibits monoamine oxidase and nitric oxide synthase to some degree, which underlies both its proposed cognitive effects and its serious interaction potential with serotonergic drugs.

## Reported benefits

- Explored for potential mitochondrial and cellular energy support at low doses
- Established clinical use for methemoglobinemia at higher, medically supervised doses
- Of interest for cognitive-clarity and antioxidant research
- Investigated in preclinical models for neuroprotective potential

## Reported side effects

- Discolors urine and stool blue-green (harmless but expected)
- Risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs
- Contraindicated in G6PD deficiency due to hemolysis risk
- Nausea, dizziness, or headache at higher doses

## Common protocols

- Low-dose oral daily use for cognitive support
- Short cycles paired with mitochondrial-support stacks

## Stacking notes

Must not be combined with serotonergic drugs (SSRIs, SNRIs, MAOIs) due to serotonin syndrome risk; use caution in G6PD deficiency.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer